NCT00277472View on ClinicalTrials.gov

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension

PHASE4CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

November 30, 2005

Conditions
Hypertension
Interventions
DRUG

Valsartan/Hydrochlorothiazide

160/12.5 mg taken once daily orally

DRUG

HCTZ

25 mg taken once daily orally

Trial Locations (1)

07936

Novartis, East Hanover

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY